J&J denied extension of patent on TB drug, to benefit patients

This month, the Indian Patent Office denied the last of the three Janssen patent extension applications for bedaquiline. While TB treatment is generally covered by the Indian government, long acting injectables are not, making the long acting version of bedaquiline inaccessible to millions. This final ruling will allow for the continued expansion of access to treatment across the country. Read more here.